VTL Vital Therapies Inc.

0.26
0  0%
Previous Close 0.26
Open 0.25
Price To Book 0.76
Market Cap 10876300
Shares 42,369,694
Volume 584,442
Short Ratio
Av. Daily Volume 4,272,214

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167728
  2. 8-K - Current report 181167718
  3. 8-K - Current report 181142166
  4. 8-K - Current report 181119135
  5. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181074586

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released September 11, 2018 - endpoints not met.
VTI-308
Alcohol-induced liver decompensation, or AILD
Terminated September 2015 in order to reduce costs
ELAD (VTI-210)
Severe acute alcoholic hepatitis
Terminated September 2015 in order to reduce costs
ELAD (VTI-212)
Fulminant hepatic failure, or FHF, or surgery-induced acute liver failure, or SILF

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167728
  2. 8-K - Current report 181167718
  3. 8-K - Current report 181142166
  4. 8-K - Current report 181119135
  5. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181074586
  6. 8-K - Current report 181069970
  7. 8-K - Current report 181065898
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 18998163
  9. 8-K - Current report 18997934
  10. EFFECT - Notice of Effectiveness 18898001